Hospitals can only watch as big players move in on primary care

The primary care business is getting more crowded at the top, where the big money is.

Last week Blue Cross and Blue Shield of Texas announced it would partner with Sanitas USA to open 10 centers offering advanced primary-care services in Dallas and Houston.

This week Forbes healthcare analyst Bruce Japsen suggested the move should worry hospitals and health systems already concerned about healthcare’s gatekeepers working under big drugstore chains and investor-backed payers.

“Health insurers are moving away from fee-for-service medicine to value-based models that pay medical care providers based on quality of care and health outcomes of patients,” Japsen wrote. “If providers and insurers are even more integrated, supporters of such arrangements believe quality and costs can be more closely monitored.”

He noted the centers in Texas will include urgent care, lab and diagnostic imaging services, wellness and disease management—and some will take walk-ins 365 days a year, welcoming patients who would otherwise go to a hospital ER.

Japsen also found patients cared for in Sanitas clinics in Florida had 32% lower hospital admission rates in 2018.

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.